Leirisalo-Repo, M., Kautiainen, H., Laasonen, L., Korpela, M., Kauppi, M.J., Kaipiainen-Seppänen, O., et al. (2013) Infliximab for 6 Months Added on Combination Therapy in Early Rheumatoid Arthritis: 2-Year Results from an Investigator-Initiated, Randomised, Double-Blind, Placebo-Controlled Study (the NEO-RACo Study). Annals of the Rheumatic Diseases, 72, 851-857.
http://dx.doi.org/10.1136/annrheumdis-2012-201365

has been cited by the following article:

• TITLE: Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions

  AUTHORS: Zuhal Örnek, Metin Işık, Nesibe Karahan Yeşil, İsmail Doğan, Hatice Şahin, Ali Erdem Baki

  KEYWORDS: DMARD, Rational, EULAR, ACR

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.5 No.4, November 2, 2015

  ABSTRACT: Disease modifying anti-rheumatic agents are the cornerstone in management of Rheumatoid Arthritis and when used correctly they are life-saving. As the number of the agents increases, detailed guidelines become more and more important for clinicians to set safe and effective regimens. Herein, we combined the EULAR and ACR recommendations for clinicians and also pointed some important facts peculiar to our country.